Skip to main content
Top
Published in:

Open Access 01-12-2024 | Pyelonephritis | Case Report

Urothelial carcinoma of the renal pelvis with squamous and sarcomatoid differentiation complicated by hydronephrosis and pyelonephritis: a case report and literature review

Authors: Zheng-ping Yang, Guan-tian Yang, Zheng Zeng, Zhuang Gong

Published in: BMC Urology | Issue 1/2024

Login to get access

Abstract

Background

Renal pelvic urothelial carcinoma with multiple histological variants co-occurs with hydronephrosis and pyelonephritis extremely rarely. The diagnosis of renal pelvic urothelial carcinoma can be complicated by these conditions, leading to delayed or missed diagnosis or misdiagnosis.

Case presentation

We report the evolutionary course of a rare case of renal pelvic urothelial carcinoma containing squamous and sarcomatoid differentiation associated with hydronephrosis and pyelonephritis in a low-functioning kidney. Preoperative clinical and imaging manifestations were highly suggestive of hydronephrosis and pyelonephritis; however, all corresponding therapeutic measures failed. Eventually, nephrectomy was performed, and postoperative pathological examination revealed renal pelvic urothelial carcinoma with squamous and sarcomatoid differentiation. Further residual ureter and bladder cuff resection was refused by the patient. Regular cisplatin-based postoperative chemotherapy and bladder perfusion were arranged, and cystoscopy and imaging examinations were performed regularly for follow-up.

Conclusion

Hydronephrosis and pyelonephritis can mask the typical clinical and imaging manifestations of renal pelvic urothelial carcinoma. Renal pelvic malignancy should be considered in patients with intractable pyelonephritis and hydronephrosis. There is no standard treatment for renal pelvic carcinoma with multiple pathological types. Radical surgery is considered an appropriate option and should be performed as early as possible. Chemotherapy and immunotherapy may improve patient survival.
Literature
1.
go back to reference Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.CrossRefPubMed Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.CrossRefPubMed
2.
go back to reference Rolim I, Henriques V, Rolim N, et al. Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Arch. 2020;477(1):111–20.CrossRefPubMed Rolim I, Henriques V, Rolim N, et al. Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. Virchows Arch. 2020;477(1):111–20.CrossRefPubMed
3.
go back to reference Terada T. Urinary bladder carcinoma with triplicate differentiations into giant cell sarcomatoid carcinoma, squamous cell carcinoma, and papillary urothelial transitional cell carcinoma: a case report. Cases J. 2009;2:9111.CrossRefPubMedPubMedCentral Terada T. Urinary bladder carcinoma with triplicate differentiations into giant cell sarcomatoid carcinoma, squamous cell carcinoma, and papillary urothelial transitional cell carcinoma: a case report. Cases J. 2009;2:9111.CrossRefPubMedPubMedCentral
4.
go back to reference Yaldiz M, Cosansu NC, Solak B, et al. Synchronous papillary urothelial carcinoma of the bladder and squamous cell carcinoma with sarcomatoid differentiation: a case report. Oncol Lett. 2016;12(5):3475–7.CrossRefPubMedPubMedCentral Yaldiz M, Cosansu NC, Solak B, et al. Synchronous papillary urothelial carcinoma of the bladder and squamous cell carcinoma with sarcomatoid differentiation: a case report. Oncol Lett. 2016;12(5):3475–7.CrossRefPubMedPubMedCentral
5.
go back to reference Yavuzsan AH, Yesildal C, Kirecci SL, et al. Radical cystectomy and Ileal Conduit diversion for bladder Urothelial Carcinoma with Sarcomatoid and squamous variants after renal transplantation. Cureus. 2020;12(5):e7935.PubMedPubMedCentral Yavuzsan AH, Yesildal C, Kirecci SL, et al. Radical cystectomy and Ileal Conduit diversion for bladder Urothelial Carcinoma with Sarcomatoid and squamous variants after renal transplantation. Cureus. 2020;12(5):e7935.PubMedPubMedCentral
6.
go back to reference Attia A, Siriwardana A, Desai D. Sarcomatoid urothelial carcinoma of the ureter with heterologous elements of chondrosarcoma and osteosarcoma, and concurrent divergent squamous differentiation: a rare case report. Urol Case Rep. 2020;34:101484.CrossRefPubMedPubMedCentral Attia A, Siriwardana A, Desai D. Sarcomatoid urothelial carcinoma of the ureter with heterologous elements of chondrosarcoma and osteosarcoma, and concurrent divergent squamous differentiation: a rare case report. Urol Case Rep. 2020;34:101484.CrossRefPubMedPubMedCentral
7.
go back to reference Ren S, Feng H, Bao Y, et al. Ureteral urothelial carcinoma with squamous cell carcinoma and sarcomatoid carcinoma differentiation: a case report. BMC Surg. 2021;21(1):96.CrossRefPubMedPubMedCentral Ren S, Feng H, Bao Y, et al. Ureteral urothelial carcinoma with squamous cell carcinoma and sarcomatoid carcinoma differentiation: a case report. BMC Surg. 2021;21(1):96.CrossRefPubMedPubMedCentral
8.
go back to reference Fikri J, Almalki AM, Almalki SA, et al. Upper urinary tract Urothelial Carcinoma with squamous, glandular, and Sarcomatoid variants in a horseshoe kidney: a Novel Case Report and Literature Review. Cureus. 2021;13(11):e19627.PubMedPubMedCentral Fikri J, Almalki AM, Almalki SA, et al. Upper urinary tract Urothelial Carcinoma with squamous, glandular, and Sarcomatoid variants in a horseshoe kidney: a Novel Case Report and Literature Review. Cureus. 2021;13(11):e19627.PubMedPubMedCentral
9.
go back to reference Kumar Pal A, Srinivas BH, Kalra S, et al. Sarcomatoid Urothelial Carcinoma of the urinary bladder with Chondrosarcomatous and concurrent divergent squamous cell carcinoma Differentiation- A Rare Entity. Cureus. 2022;14(12):e33107.PubMedPubMedCentral Kumar Pal A, Srinivas BH, Kalra S, et al. Sarcomatoid Urothelial Carcinoma of the urinary bladder with Chondrosarcomatous and concurrent divergent squamous cell carcinoma Differentiation- A Rare Entity. Cureus. 2022;14(12):e33107.PubMedPubMedCentral
10.
go back to reference Antonov P, Raycheva G, Ivanov G, et al. Hybrid bladder tumor: Urothelial Carcinoma with squamous cell differentiation, Urothelial Sarcomatoid Carcinoma, and concurrent primary mucinous adenocarcinoma with metastasis to the Penis. Cureus. 2024;16(9):e68894.PubMedPubMedCentral Antonov P, Raycheva G, Ivanov G, et al. Hybrid bladder tumor: Urothelial Carcinoma with squamous cell differentiation, Urothelial Sarcomatoid Carcinoma, and concurrent primary mucinous adenocarcinoma with metastasis to the Penis. Cureus. 2024;16(9):e68894.PubMedPubMedCentral
11.
go back to reference Cowan NC, Turney BW, Taylor NJ, et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int. 2007;99(6):1363–70.CrossRefPubMed Cowan NC, Turney BW, Taylor NJ, et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int. 2007;99(6):1363–70.CrossRefPubMed
12.
go back to reference Janisch F, Shariat SF, Baltzer P, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol. 2020;38(5):1165–75.CrossRefPubMed Janisch F, Shariat SF, Baltzer P, et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol. 2020;38(5):1165–75.CrossRefPubMed
13.
go back to reference Razavi SA, Sadigh G, Kelly AM, et al. Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic. Acad Radiol. 2012;19(9):1134–40.CrossRefPubMed Razavi SA, Sadigh G, Kelly AM, et al. Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic. Acad Radiol. 2012;19(9):1134–40.CrossRefPubMed
14.
go back to reference Takahashi N, Glockner JF, Hartman RP, et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol. 2010;183(4):1330–65.CrossRefPubMed Takahashi N, Glockner JF, Hartman RP, et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol. 2010;183(4):1330–65.CrossRefPubMed
15.
go back to reference Messer J, Shariat SF, Brien JC, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011;108(5):701–5.CrossRefPubMed Messer J, Shariat SF, Brien JC, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011;108(5):701–5.CrossRefPubMed
16.
go back to reference Subiela JD, Territo A, Mercadé A, et al. Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(11):1989–97.CrossRefPubMed Subiela JD, Territo A, Mercadé A, et al. Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(11):1989–97.CrossRefPubMed
17.
go back to reference Sharma V, Miest TS, Juvet TS, et al. The impact of Upper Tract Urothelial Carcinoma Diagnostic modality on Intravesical recurrence after Radical Nephroureterectomy: a single Institution Series and updated Meta-analysis. J Urol. 2021;206(3):558–67.CrossRefPubMed Sharma V, Miest TS, Juvet TS, et al. The impact of Upper Tract Urothelial Carcinoma Diagnostic modality on Intravesical recurrence after Radical Nephroureterectomy: a single Institution Series and updated Meta-analysis. J Urol. 2021;206(3):558–67.CrossRefPubMed
18.
go back to reference Mori K, Janisch F, Parizi MK, et al. Prognostic value of variant histology in Upper Tract Urothelial Carcinoma Treated with nephroureterectomy: a systematic review and Meta-analysis. J Urol. 2020;203(6):1075–84.CrossRefPubMed Mori K, Janisch F, Parizi MK, et al. Prognostic value of variant histology in Upper Tract Urothelial Carcinoma Treated with nephroureterectomy: a systematic review and Meta-analysis. J Urol. 2020;203(6):1075–84.CrossRefPubMed
19.
go back to reference Tang Q, Xiong G, Li X, et al. The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol. 2016;34(6):871–7.CrossRefPubMed Tang Q, Xiong G, Li X, et al. The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol. 2016;34(6):871–7.CrossRefPubMed
20.
go back to reference Wang X, MacLennan GT, Zhang S, et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol. 2009;40(2):211–7.CrossRefPubMed Wang X, MacLennan GT, Zhang S, et al. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Hum Pathol. 2009;40(2):211–7.CrossRefPubMed
21.
go back to reference Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma collaboration. Cancer. 2009;115(6):1224–33.CrossRefPubMed Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma collaboration. Cancer. 2009;115(6):1224–33.CrossRefPubMed
22.
go back to reference Kondo T, Nakazawa H, Ito F, et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 2007;178(4 Pt 1):1212–7.CrossRefPubMed Kondo T, Nakazawa H, Ito F, et al. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 2007;178(4 Pt 1):1212–7.CrossRefPubMed
23.
go back to reference Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, et al. Potential benefit of Lymph Node Dissection during Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder Cancer. Eur Urol Focus. 2019;5(2):224–41.CrossRefPubMed Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, et al. Potential benefit of Lymph Node Dissection during Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a systematic review by the European Association of Urology Guidelines Panel on non-muscle-invasive bladder Cancer. Eur Urol Focus. 2019;5(2):224–41.CrossRefPubMed
24.
go back to reference Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Carcinoma: 2023 update. Eur Urol. 2023;84(1):49–64.CrossRefPubMed Rouprêt M, Seisen T, Birtle AJ, et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Carcinoma: 2023 update. Eur Urol. 2023;84(1):49–64.CrossRefPubMed
25.
go back to reference Margulis V, Puligandla M, Trabulsi EJ, et al. Phase II trial of Neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high Grade Upper Tract Urothelial Carcinoma. J Urol. 2020;203(4):690–8.CrossRefPubMed Margulis V, Puligandla M, Trabulsi EJ, et al. Phase II trial of Neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high Grade Upper Tract Urothelial Carcinoma. J Urol. 2020;203(4):690–8.CrossRefPubMed
26.
go back to reference Meng X, Chao B, Vijay V, et al. High response rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology. 2019;129:146–52.CrossRefPubMed Meng X, Chao B, Vijay V, et al. High response rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology. 2019;129:146–52.CrossRefPubMed
27.
go back to reference Coleman JA, Yip W, Wong NC, et al. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for patients with high-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023;41(8):1618–25.CrossRefPubMedPubMedCentral Coleman JA, Yip W, Wong NC, et al. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for patients with high-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023;41(8):1618–25.CrossRefPubMedPubMedCentral
28.
go back to reference Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: a 2020 systematic review and Meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79(5):635–54.CrossRefPubMed Leow JJ, Chong YL, Chang SL, et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: a 2020 systematic review and Meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79(5):635–54.CrossRefPubMed
29.
go back to reference Birtle AJ, Jones R, Chester J, et al. Improved Disease-Free Survival with Adjuvant Chemotherapy after Nephroureterectomy for Upper Tract Urothelial Cancer: final results of the POUT Trial. J Clin Oncol. 2024;42(13):1466–71.CrossRefPubMed Birtle AJ, Jones R, Chester J, et al. Improved Disease-Free Survival with Adjuvant Chemotherapy after Nephroureterectomy for Upper Tract Urothelial Cancer: final results of the POUT Trial. J Clin Oncol. 2024;42(13):1466–71.CrossRefPubMed
30.
go back to reference Tully KH, Krimphove Md MJ, Huynh MJ, et al. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol. 2020;38(9):2227–36.CrossRefPubMed Tully KH, Krimphove Md MJ, Huynh MJ, et al. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol. 2020;38(9):2227–36.CrossRefPubMed
31.
go back to reference Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in muscle-invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102–14.CrossRefPubMedPubMedCentral Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in muscle-invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102–14.CrossRefPubMedPubMedCentral
32.
go back to reference Holmäng S, Lele SM, Johansson SL. Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol. 2007;178(1):51–6.CrossRefPubMed Holmäng S, Lele SM, Johansson SL. Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol. 2007;178(1):51–6.CrossRefPubMed
Metadata
Title
Urothelial carcinoma of the renal pelvis with squamous and sarcomatoid differentiation complicated by hydronephrosis and pyelonephritis: a case report and literature review
Authors
Zheng-ping Yang
Guan-tian Yang
Zheng Zeng
Zhuang Gong
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2024
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-024-01651-0